A61K 40/4238
Regulators of development
Official title: {Regulators of development}
A61K40/4238 (Regulators of development) appears on 84 US grants and 198 published applications in this corpus.
Search patents in A61K- Granted patents
- 84
- Published applications
- 198
- Assignees
- 121
- Inventors
- 358
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 2 |
| 2003 | 1 | 9 |
| 2004 | 1 | 4 |
| 2005 | 0 | 3 |
| 2006 | 0 | 8 |
| 2007 | 0 | 5 |
| 2008 | 2 | 4 |
| 2009 | 0 | 3 |
| 2010 | 4 | 8 |
| 2011 | 3 | 6 |
| 2012 | 6 | 6 |
| 2013 | 6 | 3 |
| 2014 | 1 | 7 |
| 2015 | 4 | 8 |
| 2016 | 3 | 5 |
| 2017 | 5 | 7 |
| 2018 | 5 | 7 |
| 2019 | 5 | 7 |
| 2020 | 4 | 14 |
| 2021 | 5 | 11 |
| 2022 | 6 | 17 |
| 2023 | 3 | 15 |
| 2024 | 4 | 15 |
| 2025 | 11 | 13 |
| 2026 | 5 | 11 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer22 Sep 2026US 12,742,153 B2Children's National Medical Center
- T cell receptors recognizing R273C or Y220C mutations in P531 Sep 2026US 12,721,890 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Targeted T-cell therapy for treatment of multiple myeloma31 Mar 2026US 12,590,292 B2Children's National Medical Center
- Cyclin A1 specific T cell receptors and uses thereof10 Mar 2026US 12,570,712 B2Fred Hutchinson Cancer Center
- T cell receptors and methods of use thereof10 Mar 2026US 12,570,715 B2University Health Network
- Plasmacytoid dendritic cells for treating cancer17 Sep 2026US 2026/0272977 A1Pdc Line Pharma
- Plasmacytoid dendritic cells and immune checkpoint inhibitor for cancer treatment13 Aug 2026US 2026/0232798 A1Pdc Line Pharma
- T cell receptors targeting tp53 hotspot mutations and uses thereof13 Aug 2026US 2026/0232801 A1Memorial Hospital for Cancer and Allied Diseases
- T-Cell Receptors13 Aug 2026US 2026/0232802 A1Ospedale San Raffaele S.R.L.
- Mutant kras-specific tcrs18 Jun 2026US 2026/0166146 A1The Johns Hopkins University
Most cited
By later US patents
- HLA class I A2 tumor associated antigen peptides and vaccine compositions58US 6,602,510 B1Epimmune Inc. · 2003
- P53-specific T cell receptor for adoptive immunotherapy41US 6,770,749 B2City of Hope · 2004
- In vivo activation of tumor-specific cytotoxic T cells25US 7,402,314 B2The Scripps Research Institute · 2008
- Tumor-associated peptides binding to MHC-molecules22US 7,396,904 B2Immatics Biotechnologies GmbH · 2008
- Cancer stem cell antigen vaccines and methods20US 8,129,184 B2Cedars-Sinai Medical Center · 2012